Last €0.47 EUR
Change Today 0.00 / 0.00%
Volume 0.0
MERR On Other Exchanges
Symbol
Exchange
Dublin
As of 12:10 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

merrion pharmaceuticals plc (MERR) Snapshot

Open
€0.47
Previous Close
€0.47
Day High
€0.47
Day Low
€0.47
52 Week High
05/24/13 - €0.64
52 Week Low
09/6/13 - €0.33
Market Cap
8.7M
Average Volume 10 Days
11.7K
EPS TTM
€0.03
Shares Outstanding
18.4M
EX-Date
--
P/E TM
18.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for MERRION PHARMACEUTICALS PLC (MERR)

Related News

No related news articles were found.

merrion pharmaceuticals plc (MERR) Related Businessweek News

No Related Businessweek News Found

merrion pharmaceuticals plc (MERR) Details

Merrion Pharmaceuticals plc engages in the development of pharmaceutical products primarily in Europe and the United States. The company develops oral dosage forms of drugs, such as tablets and capsules that have poor absorption and are given by injection. Its product pipeline includes Orazol, an oral zoledronic acid tablet, which is in Phase III clinical development for the treatment of metastatic bone disease and breast cancer; Almerol, a dosage form of alendronate that is in Phase I/II clinical development for osteoporosis; Acyline, an oral GnRH antagonist that uses GIPET technology for treating oncology and other indications; and MER-102, a development stage product for the treatment of deep vein thrombosis. The company also has two license agreements with Novo Nordisk A/S to develop and commercialize oral forms of Novo Nordisk’s insulin and GLP-1 using its proprietary GIPET technology, as well as collaborations with pharmaceutical companies, such as Ferring Pharmaceuticals, Rebel Pharmaceuticals, and others. Merrion Pharmaceuticals plc was founded in 2003 and is based in Dublin, Ireland.

1 Employees
Last Reported Date: 06/12/13
Founded in 2003

merrion pharmaceuticals plc (MERR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

merrion pharmaceuticals plc (MERR) Key Developments

Merrion Pharmaceuticals plc Announces Executive Changes, Effective January 1, 2014

Merrion Pharmaceuticals plc announced that John Fox has been appointed as Chief Executive Officer and as a director with effect from January 1, 2014. In addition, the board has appointed Michael McKenna as non executive Chairman in place of Michael Donnelly who is stepping down from his current role as Executive Chairman.

Merrion Pharmaceuticals plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2013

Merrion Pharmaceuticals plc announced unaudited consolidated earnings results for the six months ended June 30, 2013. For the six months, revenue from continuing operations was EUR 995,374 against EUR 235,854 a year ago. Profit from operating activities continuing operations was EUR 240,107 against loss from operating activities ­continuing operations was EUR 1,782,041 a year ago. Loss before income tax was EUR 131,432 against EUR 2,619,765 a year ago. Net loss for the year ­all attributable to equity holders of the company was EUR 131,432 against EUR 2,619,765 a year ago. Basic and diluted net loss per ordinary share was EUR 0.73 against EUR 15.28 a year ago. Net cash provided by operating activities was EUR 26,699 against net cash used in operations of EUR 1,130,256 a year ago.

Merrion Pharmaceuticals plc, Annual General Meeting, Sep 18, 2013

Merrion Pharmaceuticals plc, Annual General Meeting, Sep 18, 2013., at 10:00 GMT Standard Time. Location: the offices of ByrneWallace. Agenda: To receive and consider the consolidated financial statements of the company for the financial year ended 31 December 2012, together with the reports of the directors and auditors thereon; to re-elect Michael Joseph McKenna as director who, in accordance with article 81 of the articles of association of the company, retires by rotation and, being eligible, has offered himself for re-election; to re-elect Fintan Maher as director who, in accordance with article 81 of the articles of association of the company, retires by rotation and, being eligible, has offered himself for re-election; to re-appoint Gerard Flood who retires to formally allow the shareholders to ratify his appointment which was passed by the board on 20th August 2013; and to re-appoint KPMG as auditors to the company and to authorise the directors to fix the remuneration of the auditors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MERR:ID €0.47 EUR 0.00

MERR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MERR.
View Industry Companies
 

Industry Analysis

MERR

Industry Average

Valuation MERR Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERRION PHARMACEUTICALS PLC, please visit www.merrionpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.